TempraMed Technologies (HAM:9DY) Change In Receivables: €-0.15 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:9DY TempraMed Technologies Ltd HAM:9DY
7 GF Score
Price €0.19
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Change In Receivables?

TempraMed Technologies HAM:9DY -3.12% 7 Change In Receivables is €-0.15 Mil as of Jun. 2026. GuruFocus rates HAM:9DY with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

TempraMed Technologies's change in receivables for the quarter that ended in Jun. 2026 was €-0.01 Mil. It means TempraMed Technologies's Accounts Receivable increased by €0.01 Mil from Mar. 2026 to Jun. 2026 .

TempraMed Technologies's change in receivables for the fiscal year that ended in Dec. 2025 was €-0.03 Mil. It means TempraMed Technologies's Accounts Receivable increased by €0.03 Mil from Dec. 2024 to Dec. 2025 .

TempraMed Technologies's Accounts Receivable for the quarter that ended in Jun. 2026 was €0.20 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. TempraMed Technologies's Days Sales Outstanding for the three months ended in Jun. 2026 was 27.71.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TempraMed Technologies's liquidation value for the three months ended in Jun. 2026 was €-3.14 Mil.

TempraMed Technologies  (HAM:9DY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TempraMed Technologies's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.198/0.652*91
=27.71

2. In Ben Graham's calculation of liquidation value, TempraMed Technologies's accounts receivable are only considered to be worth 75% of book value:

TempraMed Technologies's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.024-3.527+0.75 * 0.198+0.5 * 0.424
=-3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Change In Receivables Related Terms

TempraMed Technologies Change In Receivables Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Change In Receivables Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Change In Receivables
0.00 -0.13 -0.03

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.03 -0.10 -0.07 -0.01
HAM:9DY
7GF Score
TempraMed Technologies Ltd HAM:9DY
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-0.15 Mil mean?
TempraMed Technologies (HAM:9DY) has a Change In Receivables of €-0.15 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for TempraMed Technologies and its competitors.
Is TempraMed Technologies' Change In Receivables too high?
TempraMed Technologies' current Change In Receivables is €-0.15 Mil. Overall, TempraMed Technologies has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Change In Receivables compare to ABT and SYK?
TempraMed Technologies' Change In Receivables of €-0.15 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for TempraMed Technologies and its competitors. TempraMed Technologies's current Change In Receivables is €-0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (HAM:9DY) has a current Change In Receivables of €-0.15 Mil. The current Change In Receivables is €-0.15 Mil. TempraMed Technologies' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For TempraMed Technologies (HAM:9DY), the current Change In Receivables is €-0.15 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
7GF Score

Get the complete analysis for HAM:9DY

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price